Examestane in advanced or recurrent endometrial carcinoma: A prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Lindemann, Kristina ^a   Malander, Susanne ^b   Christensen, Rene D ^c   Mirza, Mansoor R ^d   Kristensen, Gunnar B ^a   Aavall Lundqvist, Elisabeth ^e   Vergote, Ignace ^f   Rosenberg, Per ^g   Boman, Karin ^h   Nordstrøm, Britta ^e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d Rigshospitalet   (Denmark)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g University Hospital   (Sweden)

^h UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Aromatase inhibitor; Endometrial cancer; Exemestane; Phase II study; Treatment

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; DENMARK; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NORWAY; PROSPECTIVE STUDIES; SOCIETIES, MEDICAL; SWEDEN;

EID: 84893190700     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-68     Document Type: Article

References (16)

1. Parkin DM, Ferlay J, Curado MP, Bray F, Edwards B, Shin HR, Forman D. Fifty years of cancer incidence: CI5 I-IX. Int J Cancer J Int Du Cancer 2010, 127(12):2918-2927.
2. Lindemann K, Eskild A, Vatten LJ, Bray F. Endometrial cancer incidence trends in Norway during 1953-2007 and predictions for 2008-2027. Int J Cancer J Int Du Cancer 2010, 127(11):2661-2668.
3. Jongen V, Briet J, de Jong R, ten Hoor K, Boezen M, van der Zee A, Nijman H, Hollema H. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and-B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 2009, 112(3):537-542. 10.1016/j.ygyno.2008.10.032, 19108875.
4. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 2007, 17(5):964-978. 10.1111/j.1525-1438.2007.00897.x, 17442022.
5. Singh M, Zaino RJ, Filiaci VJ, Leslie KK. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 2007, 106(2):325-333. 10.1016/j.ygyno.2007.03.042, 17532033.
6. Kauppila A. Progestin therapy of endometrial, breast and ovarian carcinoma: a review of clinical observations. Acta obstetricia et gynecologica Scandinavica 1984, 63(5):441-450. 10.3109/00016348409156700, 6238499.
7. Sehouli J, Koensgen D, Oskay-Ozcelik G, Mustea A. New aspects of adjuvant therapy in endometrial cancer: current standards and future directions. Critical Rev Oncol/Hematol 2008, 67(3):204-212.
8. Kokka F, Brockbank E, Oram D, Gallagher C, Bryant A. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev 2010, 12:CD007926.
9. Judd HL, Shamonki IM, Frumar AM, Lagasse LD. Origin of serum estradiol in postmenopausal women. Obstetrics Gynecol 1982, 59(6):680-686.
10. Ma BB, Oza A, Eisenhauer E, Stanimir G, Carey M, Chapman W, Latta E, Sidhu K, Powers J, Walsh W, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers-a study of the national cancer institute of canada clinical trials group. Int J Gynecol Cancer 2004, 14(4):650-658. 10.1111/j.1048-891X.2004.14419.x, 15304161.
11. Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 2000, 78(2):212-216. 10.1006/gyno.2000.5865, 10926805.
12. Lintermans A, Neven P, Paridaens R. Drug safety evaluation of exemestane. Expert Opin Drug Safety 2011, 10(3):473-487.
13. Nordstrom BM, De Pont Christensen R, Oksefjell H, Kristensen G. Exemestane in advanced and recurrent endometrial carcinoma: a phase II study by NSGO. ASCO Ann Meeting Proc 2006, 24:266s.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216. 10.1093/jnci/92.3.205, 10655437.
15. National Cancer Institute Common toxicity criteria, toxical scale, version 2.0. http://www.cancer.gov. 1999, National Cancer Institute.
16. Slomovitz BSP, Levenback C, Brown J, Wolf J, Schmeler K, Johnston T, Mura D, Stone RL, Lu K, Coleman RL. Everolimus and letrozole in women with previously treated recurrent endometrial cancer: a multiinstitutional phase II clinical trial. Int J Gynecol Cancer 2012, 22(suppl. 3):8.